Actas Urol Esp (Engl Ed)

1. ALVAREZ-OSSORIO JL, Alvarez-Maestro M, Cozar-Olmo JM, Espinosa-Bosch M, et al
   Recommendations for the prevention and treatment of adverse effects of intravesical BCG.
   Actas Urol Esp (Engl Ed). 2026;50:502005.
   

   >> Share

   
   

   
   Asia Pac J Oncol Nurs

2. YANG Y, Han L, Li J, Xue J, et al
   Social alienation among people with bladder cancer: A combined structural equation modeling and fuzzy-set qualitative comparative analysis.
   Asia Pac J Oncol Nurs. 2026;13:101025.
   

   >> Share

   
   
3. ZHU K, Zhang Y, Wang Y, Chen L, et al
   Shared decision-making experiences regarding urinary diversion among Chinese patients with muscle-invasive bladder cancer: A qualitative study.
   Asia Pac J Oncol Nurs. 2026;13:101024.
   

   >> Share

   
   

   
   Biochemistry (Mosc)

4. WEI B, Liu T, Chang X, Guo L, et al
   Celastrol Sensitizes Bladder Cancer to Gemcitabine by Regulating LINC00839-Mediated Homologous Recombination DNA Repair.
   Biochemistry (Mosc). 2026;91:1704-1715.
   

   >> Share

   
   

   
   BMC Urol

5. BUZOIANU MM, Andras I, Vesa S, Giurgiu L, et al
   A single-institutional analysis of laparoscopic 3D radical cystectomy with intracorporeal urinary diversion.
   BMC Urol. 2026;26:238.
   

   >> Share

   
   

   
   BMJ Case Rep

6. CRONIN C, Lokeshwar SD, Calagua C, Garman TS, et al
   Adamantinoma-like Ewing sarcoma of the bladder.
   BMJ Case Rep. 2026;19:e270671.
   

   >> Share

   
   

   
   Cancer Treat Res Commun

7. MOCHIZUKI T, Ishiguro Y, Takeshima T, Hashizume A, et al
   Elevated expression of olfactory receptor 51T1 is associated with malignant potential of bladder cancer.
   Cancer Treat Res Commun. 2026;49:101467.
   

   >> Share

   
   

   
   Cell Mol Immunol

8. BAI M, Liu T, Wu H, Yang X, et al
   IGF2BP2 remodels the lung metastatic immune microenvironment to promote bladder cancer metastasis.
   Cell Mol Immunol. 2026 Oct 9. doi: 10.1038/s41423-026-01474.
   

   >> Share

   
   

   
   Chem Biol Interact

9. LI W, Chen Z, Deng M, Wang S, et al
   Sodium arsenite inhibits ALKBH7 increasing tRNA m(2)(2)G methylation in mitochondrial respiratory chain complex-flankng to drive malignant phenotype of bladder epithelial cells.
   Chem Biol Interact. 2026;439:112326.
   

   >> Share

   
   

   
   Chonnam Med J

10. KIM MS, Lim DG, Jung SI, Hwang EC, et al
    Screening Bacteriuria Using the Sysmex UF-5000 during Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer.
    Chonnam Med J. 2026;62:99-106.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

11. VAEZI A, Mossavarali S, Raznahan M, Haddad M, et al
    Log Odds of Positive Lymph Nodes as a Novel Prognostic Predictor for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2026 Sep 21:102664. doi: 10.1016/j.clgc.2026.102664.
    

    >> Share

    
    

    
    Cytopathology

12. CORBIN H, Khader S, Quiroga-Garza G, Pantanowitz L, et al
    When Small Cells Matter: Diagnosing Bladder Small Cell Carcinoma on Urine Cytology.
    Cytopathology. 2026;37:667-672.
    

    >> Share

    
    

    
    Diagn Cytopathol

13. MENON A, Koch R, Abramovich C
    Photo Quiz: Globose Yeast-Like Forms With Multiple Peripheral Buds in Urine and Cervical Cytology.
    Diagn Cytopathol. 2026;54:842-845.
    

    >> Share

    
    

    
    ESMO Open

14. MAIORANO BA, Necchi A
    Indirect comparison of reconstructed individual patient data from KEYNOTE-905/EV-303 and PURE-01: complementary analyses for interpreting event-free survival in muscle-invasive bladder cancer.
    ESMO Open. 2026;11:108597.
    

    >> Share

    
    
15. ZUGMAN M, Kirche Duarte I, Baccaglini W
    The cost of intensification in high-risk non-muscle-invasive bladder cancer.
    ESMO Open. 2026;11:108598.
    

    >> Share

    
    

    
    Eur Urol

16. AYDOGDU C, Bukavina L, Cheng L, Al-Ahmadie HA, et al
    Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.
    Eur Urol. 2026;90:377-388.
    

    >> Share

    
    
17. MOLLICA V, Rosellini M, Santoni M, Massari F, et al
    Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer.
    Eur Urol. 2026 Oct 7:S0302-2838(26)02409-7. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Fr J Urol

18. MATHEZ W, Briche V, Vincentelli A, Bruyere F, et al
    Clinical utility of routine urine culture before intravesical mitomycin C instillation: A retrospective instillation-based study.
    Fr J Urol. 2026;36:103154.
    

    >> Share

    
    
19. LEON P, Long Depaquit T, Audenet F, Allory Y, et al
    Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC.
    Fr J Urol. 2026;36:103156.
    

    >> Share

    
    

    
    Front Cell Dev Biol

20. LI S, Zhang Y, Mao T, Wei J, et al
    Aromatic amine exposure and bladder cancer: a review of recent advances in epidemiology, pathogenesis, and prevention.
    Front Cell Dev Biol. 2026;14:1914792.
    

    >> Share

    
    

    
    Front Oncol

21. SHI G, Wu Y, Wang Y, Wang S, et al
    The deubiquitinating enzyme UCHL3 promotes bladder cancer progression and glycolysis through enhancing PKM2 protein stability.
    Front Oncol. 2026;16:1883763.
    

    >> Share

    
    
22. XU X, Hao HY, Chen HY
    The clinical landscape of bladder cancer treatment: a brief report on new developments and future perspectives in pharmaceutical interventions.
    Front Oncol. 2026;16:1747070.
    

    >> Share

    
    

    
    Front Pharmacol

23. ZHANG XZ, Xiang JA, Yang LC, Li YD, et al
    Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence.
    Front Pharmacol. 2026;17:1921622.
    

    >> Share

    
    
24. WANG H, Liu H, Ma X, Wang W, et al
    Structure-based virtual screening identifies ethyl rosmarinate as a SLC1A6-targeted therapeutic candidate for bladder cancer.
    Front Pharmacol. 2026;17:1895264.
    

    >> Share

    
    

    
    Int J Urol

25. IKEDA R, Yoshida S, Chen W, Fujiwara M, et al
    Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis.
    Int J Urol. 2026;33:e70667.
    

    >> Share

    
    

    
    IUBMB Life

26. 
    Correction to "MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model".
    IUBMB Life. 2026;78:e70134.
    

    >> Share

    
    

    
    J Clin Ultrasound

27. MENEGHESSO D, Pasquinucci M, Bruniera M, Carletti F, et al
    Diagnosis by Resolution: Ultrasound Follow-Up of Neonatal Polypoid Cystitis Mimicking Botryoid Rhabdomyosarcoma.
    J Clin Ultrasound. 2026;54:2070-2074.
    

    >> Share

    
    

    
    J Int Med Res

28. YEOM JY, Kim YU, Kim J, Min J, et al
    Effect of nefopam on postoperative catheter-related bladder discomfort after transurethral resection of the bladder under general anesthesia: A randomized controlled trial.
    J Int Med Res. 2026;54:3000605261495728.
    

    >> Share

    
    

    
    J Transl Med

29. GUO B, Fu S, Li J, Cheng Q, et al
    An integrative epigenomic and single-cell framework identifies a prognostic DNA methylation risk score and ZNF638 silencing in urothelial carcinoma.
    J Transl Med. 2026;24:1264.
    

    >> Share

    
    

    
    J Urol

30. CHANG SS, Chamie K, Seabury CA, Gonzalgo ML, et al
    Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ +/- Papillary Disease.
    J Urol. 2026;216:663-675.
    

    >> Share

    
    
31. DECASTRO GJ, Joffe BI, Stein MN, Abate-Shen C, et al
    A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guerin-Unresponsive Urothelial Carcinoma of the Bladder.
    J Urol. 2026;216:676-684.
    

    >> Share

    
    

    
    JAMA Oncol

32. QIE Y, Jia K, Huang S, Zhao J, et al
    Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2026 Oct 8. doi: 10.1001/jamaoncol.2026.3909.
    

    >> Share

    
    

    
    Med Oncol

33. GENG H, Wu Y, Ma J, Zhang W, et al
    Exosomal circ55033 promotes cigarette smoke-induced bladder cancer by modulating EMT and stem cell properties.
    Med Oncol. 2026;43:326.
    

    >> Share

    
    

    
    Mod Pathol

34. MATHISEN IF, Koll FJ, Mayer RS, Schulz MH, et al
    Dual-Foundation-Model Ensemble Predicts Gene Expression in Muscle-Invasive Bladder Cancer for Patient Outcome Stratification.
    Mod Pathol. 2026 Oct 5:101092. doi: 10.1016/j.modpat.2026.101092.
    

    >> Share

    
    

    
    Mol Carcinog

35. PENG Z, Jia R, Zhang T, Yang J, et al
    CNOT4 Suppresses Bladder Cancer Progression by Promoting Ubiquitination-Mediated Degradation of EIF2AK2 and Inhibiting Autophagy.
    Mol Carcinog. 2026 Oct 6. doi: 10.1002/mc.70187.
    

    >> Share

    
    

    
    Nat Med

36. LIU KJ, Shi WY, Nesselbush MC, Phillips NA, et al
    Urine cell-free RNA for bladder cancer detection and treatment response prediction.
    Nat Med. 2026 Oct 2. doi: 10.1038/s41591-026-04673.
    

    >> Share

    
    

    
    Nat Rev Urol

37. RAGGI D, Crupi E, Dyrskjot L
    ctDNA in muscle-invasive bladder cancer - clinically actionable, not yet standardized.
    Nat Rev Urol. 2026 Oct 6. doi: 10.1038/s41585-026-01197.
    

    >> Share

    
    

    
    NPJ Precis Oncol

38. FU S, Tan Z, Shi H, Chen J, et al
    Retraction Note: Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.
    NPJ Precis Oncol. 2026;10:377.
    

    >> Share

    
    

    
    Oncologist

39. ZARKA J, Childs DS, Muniz Rincon M, Tarhini A, et al
    Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework.
    Oncologist. 2026;31:oyag371.
    

    >> Share

    
    

    
    Pain Res Manag

40. SHI L, Chen C, Li L, Chen J, et al
    Effects of Acupoint Application on Lower Urinary Tract Symptoms in Patients Undergoing Intravesical Instillation After Bladder Cancer Surgery: A Randomized Crossover Exploratory Study.
    Pain Res Manag. 2026;2026:e5079749.
    

    >> Share

    
    

    
    Pathol Int

41. JEONG JI, Lee J, Oh MH, Cho HD, et al
    MITF-Overexpressing Perivascular Epithelioid Cell Tumor of the Urinary Bladder Lacking TSC1/TSC2 Alterations and TFE3 Rearrangement: A Case Report and Review of the Literature.
    Pathol Int. 2026;76:e70187.
    

    >> Share

    
    

    
    Photodiagnosis Photodyn Ther

42. YAMAMOTO S, Fukata S, Kurano Y, Morishita Y, et al
    Fluorescence-guided local therapy for bladder and upper urinary tract cancer: a narrative review.
    Photodiagnosis Photodyn Ther. 2026;61:105617.
    

    >> Share

    
    

    
    Pragmat Obs Res

43. GORE JL, Thompson A, Kelkar SS, Chirikov V, et al
    Characteristics and Treatment Patterns of Patients with Muscle-Invasive Bladder Cancer in the United States: A Real-World Cohort Study.
    Pragmat Obs Res. 2026;17:617060.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

44. ROSHANSHAD A
    Advanced Diffusion MRI-based MR Cytometry for Quantitative Microstructural Assessment and Grading of Bladder Cancer.
    Radiol Imaging Cancer. 2026;8:e269023.
    

    >> Share

    
    

    
    Sci Bull (Beijing)

45. DU T, She Y, Li H, Liu X, et al
    Active bacteria-delivered nanosystems for multimodal bladder cancer therapy.
    Sci Bull (Beijing). 2026 Sep 22:S2095-9273(26)01178.
    

    >> Share

    
    

    
    Urol Case Rep

46. ENGELS EA, Burkett S, Ramanujan VK, Yu KJ, et al
    Donor-derived bladder cancer following kidney transplantation.
    Urol Case Rep. 2026;69:103618.
    

    >> Share

    
    

    
    Urol Oncol

47. GUZMAN T, McSweeney S, Aydogdu C, Diaz G, et al
    Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns.
    Urol Oncol. 2026 Oct 8:S1078-1439(26)00713-1. doi: 10.1016/j.urolonc.2026.
    

    >> Share

    
    

    
    Urologie

48. ZENGERLING F
    [Blue versus white light during transurethral resection of nonmuscle invasive bladder cancer].
    Urologie. 2026 Oct 6. doi: 10.1007/s00120-026-02938.
    

    >> Share

    
    

    
    Urology

49. TALLMAN JE, Hyman MJ, Agarwal PK, Faris SF, et al
    Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.
    Urology. 2026 Oct 9:S0090-4295(26)00665-5. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    

    
    World J Urol

50. PYRGIDIS N, Engelmann P, Puhr-Westerheide D, Ebner B, et al
    The effect of ureteral stenting on the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors involving the ureteral orifice.
    World J Urol. 2026;44:725.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share